Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 611

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

Open access
Lakhani, Sunil R., Reis-Filho, Jorge S., Fulford, Laura, Penault-Llorca, Frederique, van der Vijver, Marc, Parry, Suzanne, Bishop, Timothy, Benitez, Javier, Rivas, Carmen, Bignon, Yves-Jean, Chang-Claude, Jenny, Hamann, Ute, Cornelisse, Cees J., Devilee, Peter, Beckmann, Matthias W., Nestle-Krämling, Carolin, Daly, Peter A., Haites, Neva, Varley, Jenny, Lalloo, Fiona, Evans, Gareth, Maugard, Christine, Meijers-Heijboer, Hanne, Klijn, Jan G.M., Olah, Edith, Gusterson, Barry A., Pilotti, Silvana, Radice, Paolo, Scherneck, Siegfried, Sobol, Hagay, Jacquemier, Jocelyne, Wagner, Teresa, Peto, Julian, Stratton, Michael R., McGuffog, Lesley, Easton, Douglas F., the Breast Cancer Linkage Consortium·2005·Clinical Cancer Research

Abstract

Purpose: To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus 12%; CK5/6: 58% versus 7%; CK17: 53% versus 10%; osteonectin: 43% versus 19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-2424

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 7

  1. Dairkee SH, Ljung BM, Smith H, et al. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 1987;10:11–20. · doi:10.1007/bf01806130
  2. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 1995;48:26–32. · doi:10.1136/jcp.48.1.26
  3. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001;85:422–7. · doi:10.1054/bjoc.2001.1869
  4. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999;30:1134–9. · doi:10.1016/s0046-8177(99)90028-x
  5. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197–202. · doi:10.1097/00000478-200002000-00005
  6. Santini D, Ceccarelli C, Tardio ML, et al. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. Appl Immunohistochem Mol Morphol 2002;10:29–33. · doi:10.1097/00129039-200203000-00005
  7. Cortes-Funes H, Soto Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 2003;89:S3–8. · doi:10.1038/sj.bjc.6601476

Cited by

See all 611

Metadata

Authors
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., Chang-Claude, J., Hamann, U., Cornelisse, C. J., Devilee, P., Beckmann, M. W., Nestle-Krämling, C., Daly, P. A., Haites, N., Varley, J., Lalloo, F., Evans, G., Maugard, C., Meijers-Heijboer, H., Klijn, J. G. M., Olah, E., Gusterson, B. A., Pilotti, S., Radice, P., Scherneck, S., Sobol, H., Jacquemier, J., Wagner, T., Peto, J., Stratton, M. R., McGuffog, L., Easton, D. F., & the Breast Cancer Linkage Consortium
Venue
Clinical Cancer Research
Published
2005-07-15
Volume
11
Issue
14
Pages
5175-5180
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2133349592
Cited by
611
References
23
FWCI
25.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-2424
The paper
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., Chang-Claude, J., Hamann, U., Cornelisse, C. J., Devilee, P., Beckmann, M. W., Nestle-Krämling, C., Daly, P. A., Haites, N., Varley, J., . . . the Breast Cancer Linkage Consortium. (2005). Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-2424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.